The aim of this clinical study is to compare the efficacy of Elonide Nasal Spray to Nasonex Nasal Spray and Placebo (non-active ingredient) in the management of allergic rhinitis.

There are two hypotheses of this study:

1. Elonide nasal spray is same efficacy to Nasonex nasal spray.
2. Elonide nasal spray is more efficient to placebo.

There are several objectives of the study:

1. To compare the efficacy of Elonide to Nasonex and Placebo in treating allergic rhinitis via Quality of life assessments and nasal airflow improvements.
2. To compare the efficacy of Elonide to Nasonex and Placebo in treating allergic rhinitis via symptomatics improvement.
3. To assess the side effect of Nasal spray given.

Patients who meet the criteria to join the study will be randomized in a double-blind manner (patients and investigators). Patients will be given information about the study and consent form, patients will be randomized to 3 treatment group(Elonide, Nasonex, Placebo). Patients will be evaluated before and after treatment in one month time. Patients will be advised to use the nasal spray twice daily.

Inclusion Criteria:

• All adults patients 18 years and above
• Newly diagnosed mild, moderate to severe, intermittent and persistent allergic rhinitis
• Positive skin prick test or serum Immunoglobulin E

Exclusion Criteria:

• Patients who have been on allergic rhinitis treatment
• Below 18 years old
• Patients diagnosed with asthma or immunodeficiency diseases
• Pregnancy
• Other concomitant rhinology disease
• Smokers
• Severe deviated nasal septum

Data obtained through this study may be provided to qualified researchers with academic interest in allergic rhinitis.

Data can be assess 6 months after publication

Access to trial IPD can be access by qualified researchers engaging in independent scientific research.